Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT

Orthostatic hypotension (OH) is frequently observed with hypertension treatment, but its contribution to adverse outcomes is unknown. The SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized trial of adults, age ≥50 years at high risk for cardiovascular disease with a seated systolic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hypertension (Dallas, Tex. 1979) Tex. 1979), 2020-03, Vol.75 (3), p.660-667
Hauptverfasser:	Juraschek, Stephen P., Taylor, Addison A., Wright, Jackson T., Evans, Gregory W, Miller, Edgar R., Plante, Timothy B., Cushman, William C., Gure, Tanya R., Haley, William E., Moinuddin, Imran, Nord, John, Oparil, Suzanne, Pedley, Carolyn, Roumie, Christianne L., Whittle, Jeff, Wiggers, Alan, Finucane, Ciarán, Anne Kenny, Rose, Appel, Lawrence J., Townsend, Raymond R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Asymptomatic Diseases Blood Pressure Bradycardia - chemically induced Bradycardia - epidemiology Cardiovascular Diseases - epidemiology Comorbidity Female Follow-Up Studies Goals Humans Hypertension - drug therapy Hypertension - epidemiology Hypotension - chemically induced Hypotension - epidemiology Hypotension, Orthostatic - chemically induced Hypotension, Orthostatic - epidemiology Male Middle Aged Proportional Hazards Models Racial Groups - statistics & numerical data Renal Insufficiency, Chronic - epidemiology Risk
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Orthostatic hypotension (OH) is frequently observed with hypertension treatment, but its contribution to adverse outcomes is unknown. The SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized trial of adults, age ≥50 years at high risk for cardiovascular disease with a seated systolic blood pressure (BP) of 130 to 180 mm Hg and a standing systolic BP ≥110 mm Hg. Participants were randomized to a systolic BP treatment goal of either
ISSN:	0194-911X 1524-4563 1524-4563
DOI:	10.1161/HYPERTENSIONAHA.119.14309